SIZE XSSIZE SMSIZE MDSIZE LG

HOPA Annual Conference 2019

Session descriptions and speaker information for Saturday, April 6, at HOPA's Annual Conference.


 

8–9:15 am

General Session (0.125 CEU)

UAN 0465-0000-19-028-L04-P
Included in Virtual Meeting blue K

Crucial Conversations for the Hematology/Oncology Pharmacist (401)

Pharmacists spend years training in oncology but do not typically have formal training in how to effect change. Pharmacists work in collaborative environments with other pharmacists and interdisciplinary teams. To be successful in creating ideal regimens for patients, updating guidelines, and working on projects, pharmacists must be able to influence others around them and have the skills to enter into crucial conversations. This session will give learners the background on influence, lateral leadership, and crucial conversations as well as discrete skills to take home and implement.

John Valgus, PharmD MHA BCOP


8–9:15 am

BCOP Session (0.125 CEU)

UAN 0465-0000-19-036-L04-P
Included in Virtual Meeting red a

Advances in Breast Cancer: Are We Moving the Needle to Better Survival? (BC5)

Breast cancer mortality is falling as a result of earlier detection, advancements in surgical techniques, improved delivery of radiotherapy, and better adjuvant medical therapies. Despite these improvements, breast cancer remains the most common women’s cancer and is the second most common cause of death in women. This session will focus on the medical treatment of breast cancer in the adjuvant and metastatic setting, with particular attention to recent advances in the role of extended adjuvant therapy and new drug therapies such as olaparib and CD4/6 inhibitors.

Sandra Cuellar, PharmD BCOP


9:30–10:45 am

General Session (0.125 CEU)

UAN 0465-0000-19-029-L04-P
Included in Virtual Meeting red A

Translating Tumor Genetics into Clinical Practice (402)

The presenter will define the role of precision medicine in the standard practice of oncology, discuss examples of translating tumor genomic findings into clinical practice, and review the available clinical trial data supporting the value of precision medicine The process of performing and interpreting tumor and cell-free DNA genetic results from commercially available testing companies will be described. The session will cover the role pharmacists can play as part of molecular tumor board development and standard operation, as well as challenges and opportunities for the continued growth of precision medicine initiatives in oncology. This session will engage the audience with examples of patient cases to increase its clinical utility for individual practice sites.

Christine Walko, PharmD BCOP FCCP


9:30–10:45 am

General Session (0.125 CEU)

UAN 0465-0000-19-030-L04-P
Included in Virtual Meeting red A

Significant Papers: Hematology (403)

Recent advances in the management of patients with hematologic malignancies have provided exciting opportunities for the oncology pharmacist to optimize patient care and outcomes. With the immense volume of new publications and data, it can be difficult to keep up with and synthesize these updates, as well as to determine how the results may affect current practice. The presenter will recap several papers published in the past year and highlight the potential implications and impact on current therapy.

Kathy Edwards, PharmD BCOP BCPS


9:30–10:45 am

BCOP Session (0.125 CEU)

UAN 0465-0000-19-037-L04-P
Included in Virtual Meeting red a

Leukemia Is Coming: The Battle of Targeted Therapies in Acute Myeloid Leukemia (BC6)

For more than 40 years, the war against acute myeloid leukemia (AML) raged, with little progress made in the standard treatment artillery, 7+3. This status changed in the past 2 years, with five novel agents added to the arsenal. This session will take an in-depth look at these targeted therapies, their mechanisms and pathways, unique toxicity profiles, and pharmcoeconomic impact. Key agents awaiting FDA decisions in early 2019 will also be discussed. We will debate clinical controversies in treatment selection and glean new understanding of the pharmacists' role in the management of AML in this new era. Let the battle of targeted therapies begin.

Bernard Marini, PharmD BCOP
Kayleigh Marx, PharmD RPh BCOP


11 am–12:15 pm

General Session (0.125 CEU)

UAN 0465-0000-19-031-L04-P
Included in Virtual Meeting red A

It's Time for Alphabet Soup! Let's Start with AIHA, ITP, TTP/HUS, and ACFD (404)

Nonmalignant disorders of the blood are rare and challenging—both to understand and to recognize—and treatment options are limited. Because of the rarity of these disorders, knowing how to recognize and treat them received less emphasis in the past, but this is no longer the case. With the use of immunotherapy in the cancer population, greater incidence of autoimmune hematological disorders has been reported; hence, the ability to recognize and recommend treatment of these disorders has gained importance. The session will focus on disorders of three main components of the blood (red blood cells, platelets, and clotting factors) and cover these blood disorders: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), acquired thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and acquired clotting factor deficiency (ACFD).

Sheh-Li Chen, PharmD BCOP


11 am–12:15 pm

BCOP Session (0.125 CEU)

UAN 0465-0000-19-038-L04-P
Included in Virtual Meeting red a

BCOP Session 7
Updates in the Management of Colorectal Cancer (BC7)

This session will review new recommendations in the treatment of colorectal cancer and equip clinical practitioners with knowledge they can apply to their practices. Topics include risk factors and risk reduction strategies; updates in screening recommendations for normal risk populations; and the application of molecular biomarkers such as MSI, KRAS and BRAF in treatment of both early- and late-stage disease. The IDEA collaboration and how results allow for the first individualization of colorectal cancer treatment based on patient disease characteristics, co-morbidities, and preference will also be examined.

Amber Draper, PharmD BCOP

xs
sm
md
lg